Please login to the form below

Not currently logged in
Email:
Password:

safinamide

This page shows the latest safinamide news and features for those working in and with pharma, biotech and healthcare.

FDA approves Newron's Parkinson's disease drug Xadago

FDA approves Newron's Parkinson's disease drug Xadago

Newron Pharmaceuticals’ Xadago (safinamide) was approved as an add-on treatment for patients already on levodopa/carbidopa and who experience ‘off’ episodes when those medications don’t work well.

Latest news

  • Newron back on track for Xadago approval in US Newron back on track for Xadago approval in US

    The Italian pharma company's partner Zambon is already rolling Xadago (safinamide) out in Europe following its EMA approval last year, and has just launched in Norway taking the tally of ... We assume the safinamide label could be expanded to include

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    neprilysin inhibitor. Novartis. USA. safinamide. Xadago. Parkinson's disease. MAO-B inhibitor. Newron Pharma.

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    Currently available therapies of this class include selegiline and rasagiline. Safinamide (Newron, Zambon and Meiji Seika Pharma) is a selective and reversible MAO B inhibitor in the absence of MAO-A

  • Oncology bias in pharma deals

    Merck Serono's decision to return the rights to Safinamide (an alpha aminoaminde in phase III, as an add-on therapy to dopamine agonists or levodopa for dyskinesia in Parkinson's ... Termination of acquisition. Safinamide (alpha aminoamide) adjunct

  • Next generation

    Safinamide (Merck Serono) is an MAOB inhibitor currently in phase III trials as an adjunctive therapy for the treatment of PD. ... However, safinamide also acts as a glutamate release inhibitor, as well as a sodium and calcium channel blocker.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....